Condition
Light Chain Amyloidosis
Total Trials
4
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Recruiting4
Clinical Trials (4)
Showing 4 of 4 trials
NCT07081646Phase 1Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT06983951Not ApplicableRecruitingPrimary
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
NCT06971380Phase 2Recruiting
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
NCT05978661Phase 1RecruitingPrimary
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Showing all 4 trials